Annual report pursuant to Section 13 and 15(d)

Strategic Alliances (Details)

v3.3.1.900
Strategic Alliances (Details) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Jan. 31, 2015
Dec. 31, 2010
Sep. 30, 2015
Mar. 31, 2015
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Jul. 31, 2015
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Revenue from sale of intellectual property         $ 0 $ 0 $ 12,500,000  
Deferred revenue         232,900,000 6,700,000    
Grant repayment       $ 25,900,000 25,889,000 0 0  
Intangible assets, net [1]         638,152,000 62,649,000    
TESARO                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Milestone payments, maximum   $ 30,000,000.0            
Upfront payment under license agreements   6,000,000            
Additional milestone payment   $ 85,000,000.0            
Milestone revenue to date         20,000,000      
Maximum period to receive royalties   12 years            
TESARO | Collaborative Arrangement, Product                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Milestone revenue recognized         15,000,000 $ 5,000,000    
Merck | Collaborative Arrangement, Product                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Amount payable each year         $ 5,000,000      
Yearly payment period         4 years      
Pfizer | Collaborative Arrangement, Product                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Non-refundable upfront payment $ 295,000,000              
Additional milestone payment to be received 275,000,000              
Revenue from sale of intellectual property         $ 65,500,000      
Deferred revenue         229,500,000      
Research and development expenses related to hGH-CTP         55,300,000      
Milestone payments, maximum 275,000,000              
RXi Pharmaceuticals Corporation                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Revenue from sale of intellectual property             12,500,000  
Milestone payments             $ 50,000,000  
Accrued Expenses | Pfizer | Collaborative Arrangement, Product                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Deferred revenue         70,600,000      
Other Long-term Liabilities | Pfizer | Collaborative Arrangement, Product                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Deferred revenue         $ 158,900,000      
Minimum                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Intangible assets, estimated useful lives         3 years      
Minimum | Pfizer | Collaborative Arrangement, Product                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Milestone payment ranges 20,000,000              
Maximum                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Intangible assets, estimated useful lives         20 years      
Maximum | Pfizer | Collaborative Arrangement, Product                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Milestone payment ranges $ 90,000,000              
Pharmsynthez                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Ownership percentage         17.00%      
Notes | Pharmsynthez Note Receivable | Pharmsynthez                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Debt face amount               $ 3,000,000.0
Licenses | Merck | Collaborative Arrangement, Product                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Intangible assets, net     $ 23,000,000   $ 18,200,000      
Intangible assets, estimated useful lives     13 years          
Licenses | Accrued Expenses | Merck | Collaborative Arrangement, Product                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Intangible assets, net         5,000,000      
Licenses | Other Long-term Liabilities | Merck | Collaborative Arrangement, Product                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Intangible assets, net         $ 13,200,000      
[1] As of December 31, 2014, total assets include $7.6 million and total liabilities include $12.1 million related to SciVac Ltd (“SciVac”). SciVac was a consolidated variable interest entity which we deconsolidated in July 2015. Refer to Note 4. SciVac’s consolidated assets were owned by SciVac and SciVac’s consolidated liabilities had no recourse against us.